Q (sonnet): <conversation_so_far>
<user>
I'm interested in IDH1 in lower grade glioma. What can we look at?
</user>

<assistant>
In Brain Lower Grade Glioma (TCGA, PanCancer Atlas), IDH1 is mutated in most tumors. A few directions:
1. Compare overall survival of IDH1-mutant vs IDH1-wild-type patients
2. See which genes are co-mutated with IDH1 (e.g. TP53, ATRX, CIC)
3. Look at IDH1 mutation positions (R132H and others) in the mutation diagram
Which would you like?
</assistant>
</conversation_so_far>

Continue this conversation: reply to the user's new message.

<user>
option 1 please
</user>

▶ resolve_and_route
{
 "studyKeywords": [
  "lower grade glioma",
  "TCGA",
  "pan_can_atlas"
 ]
}

◀ result
{"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","sampleCount":514,"studyViewUrl":"https://www.cbioportal.org/study?id=lgg_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["lgg_tcga_pan_can_atlas_2018_gistic","lgg_tcga_pan_can_atlas_2018_log2CNA","lgg_tcga_pan_can_atlas_2018_mutations","lgg_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","lgg_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","lgg_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","lgg_tcga_pan_can_atlas_2018_rppa","lgg_tcga_pan_can_atlas_2018_rppa_Zscores","lgg_tcga_pan_can_atlas_2018_structural_variants"],"genericAssayProfiles":["lgg_tcga_pan_can_atlas_2018_armlevel_cna","lgg_tcga_pan_can_atlas_2018_genetic_ancestry","lgg_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","lgg_tcga_pan_can_atlas_2018_methylation_hm450"],"heatmapProfileIds":["lgg_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","lgg_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","lgg_tcga_pan_can_atlas_2018_rppa_Zscores"],"availableComparisonTabs":["overlap","clinical","survival","alterations","mutations","mrna","protein","generic_assay_armlevel_cna","generic_assay_genetic_ancestry","generic_assay_methylation"]}}]}}

▶ navigate_to_results_view
{
 "studyIds": [
  "lgg_tcga_pan_can_atlas_2018"
 ],
 "genes": [
  "IDH1: MUT"
 ],
 "tab": "comparison/survival",
 "profileFilter": "mutations"
}

◀ result
{"success":true,"message":"Navigating to https://www.cbioportal.org/results/comparison/survival?cancer_study_list=lgg_tcga_pan_can_atlas_2018&gene_list=IDH1%3A+MUT&case_set_id=lgg_tcga_pan_can_atlas_2018_all&profileFilter=mutations","url":"https://www.cbioportal.org/results/comparison/survival?cancer_study_list=lgg_tcga_pan_can_atlas_2018&gene_list=IDH1%3A+MUT&case_set_id=lgg_tcga_pan_can_atlas_2018_all&profileFilter=mutations","data":{"studyIds":["lgg_tcga_pan_can_atlas_2018"],"studies":[{"studyId":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","sampleCount":514}],"genes":["IDH1"],"caseSetId":"lgg_tcga_pan_can_atlas_2018_all","pageDescription":"Kaplan-Meier survival analysis comparing groups defined by query genes."}}

═ answer (success)
[IDH1 mutant vs. wild-type survival comparison — LGG (TCGA, PanCancer Atlas)](https://www.cbioportal.org/results/comparison/survival?cancer_study_list=lgg_tcga_pan_can_atlas_2018&gene_list=IDH1%3A+MUT&case_set_id=lgg_tcga_pan_can_atlas_2018_all&profileFilter=mutations)

This opens the Kaplan-Meier survival comparison for the 514-sample Brain Lower Grade Glioma (TCGA, PanCancer Atlas) cohort, split into an **IDH1-mutant ("Altered")** group and an **IDH1-wild-type ("Unaltered")** group, restricted to samples with mutation profiling. On the page you can toggle between Overall Survival, Disease-Free Survival, Progression-Free Survival, and Disease-Specific Survival, and it reports log-rank p-values and can generate hazard ratios — this cohort is well known for IDH1-mutant patients showing markedly better survival, but let the plot on the page speak for that rather than taking my word for it.

If you'd like, I can also pull the raw patient counts (mutant vs. wild-type, events vs. censored) for a quick numeric summary alongside the plot — just let me know.